Collateral for a security interest recorded May 14, 2025 (LSI Financing LLC).
Term ends Jan 28, 2031 · High confidence
20-year base term ends Mar 15, 2033
Held by Eagle Pharmaceuticals, Inc.
Filed Mar 15, 2013 as application 13/838,090 · Granted May 19, 2015
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
2013
2033
Clock starts
Mar 15, 2013
Mar 15, 2013
Term ends
Jan 28, 2031
Jan 28, 2031
Granted
May 19, 2015
May 19, 2015
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,000,021.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
30
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 15, 2013, when this application, 13/838,090, was filed | Mar 15, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,000,021) | capped to Jan 28, 2031 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 28, 2031 | High confidence |
This family
| Application 61/613,173 | Provisional application no patent term | no patent term |
| Application 61/669,889 | Provisional application no patent term | no patent term |
| Application 61/678,715 | Provisional application no patent term | no patent term |
| US 9,000,021 | In force Jan 2031 | Jan 2031 |
| US 9,034,908 | this patent Jan 2031 | Jan 2031 |
| Application PCT/US2013/032289 | PCT application no patent term | no patent term |
| Application PCT/US2013/032295 | PCT application no patent term | no patent term |
| Application 14/097,904 | Abandoned not computed | not computed |
8 of 30 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 30, 2014 Reel 32791, frame 599 | Sundaram, Srikanth | Eagle Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 22, 2015 Reel 35696, frame 856 | Eagle Pharmaceuticals, Inc. | Cephalon, Inc. | License |
| Jan 26, 2017 Reel 41095, frame 554 | Eagle Pharmaceuticals, Inc. | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
| Apr 1, 2025 Reel 70703, frame 524 | JPMorgan Chase Bank, N.A., as Administrative Agent | Eagle Pharmaceuticals, Inc. | Release of Security Interest |
| May 14, 2025 Reel 71275, frame 866 | Eagle Subi LLC, a Delaware Corporation | LSI Financing LLC | Security Interest |
| Feb 18, 2026 Reel 74849, frame 457 | Eagle Pharmaceuticals, Inc. | Ankura Trust Company, LLC. | Grant of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2031
Term ends Jan 28, 2031. No further fees fall due before then
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,000,021.
Citations
42
later US patents cite this one
That is top 25% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.